Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2025)

Historic EBT Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 4249.23%.

  • Insight Molecular Diagnostics' EBT Margin rose 75029400.0% to 4249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1392.91%, marking a year-over-year increase of 47361400.0%. This contributed to the annual value of 3245.14% for FY2024, which is 15727500.0% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EBT Margin is 4249.23%, which was up 75029400.0% from 1900.0% recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' EBT Margin peaked at 2006.4% during Q1 2023, and registered a low of 11752.17% during Q3 2024.
  • For the 5-year period, Insight Molecular Diagnostics' EBT Margin averaged around 2579.24%, with its median value being 1799.78% (2023).
  • Per our database at Business Quant, Insight Molecular Diagnostics' EBT Margin soared by 541471300bps in 2021 and then crashed by -102395900bps in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' EBT Margin (Quarter) stood at 997.16% in 2021, then tumbled by -340bps to 4385.77% in 2022, then decreased by -17bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
  • Its last three reported values are 4249.23% in Q3 2025, 1900.0% for Q2 2025, and 318.01% during Q1 2025.